getAllEvidenceItems.RdRetrieve all evidence items from the CIViC DB
getAllEvidenceItems(page = 1, count = 25)
| page | the page number to retrieve |
|---|---|
| count | the number of evidence items to retrieve |
An S3 Object of type civic_api containing the content, url, and response
getAllEvidenceItems(count = 10)#> $content #> $content$`_meta` #> $content$`_meta`$current_page #> [1] 1 #> #> $content$`_meta`$per_page #> [1] "10" #> #> $content$`_meta`$total_pages #> [1] 642 #> #> $content$`_meta`$total_count #> [1] 6411 #> #> $content$`_meta`$links #> $content$`_meta`$links$`next` #> [1] "https://civicdb.org/api/evidence_items?count=10&page=2" #> #> $content$`_meta`$links$previous #> NULL #> #> #> #> $content$records #> $content$records[[1]] #> $content$records[[1]]$id #> [1] 1 #> #> $content$records[[1]]$name #> [1] "EID1" #> #> $content$records[[1]]$description #> [1] "JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL)." #> #> $content$records[[1]]$disease #> $content$records[[1]]$disease$id #> [1] 1 #> #> $content$records[[1]]$disease$name #> [1] "Lymphoid Leukemia" #> #> $content$records[[1]]$disease$display_name #> [1] "Lymphoid Leukemia" #> #> $content$records[[1]]$disease$doid #> [1] "10747" #> #> $content$records[[1]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:10747" #> #> #> $content$records[[1]]$drugs #> list() #> #> $content$records[[1]]$rating #> [1] 4 #> #> $content$records[[1]]$evidence_level #> [1] "B" #> #> $content$records[[1]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[1]]$clinical_significance #> [1] "Negative" #> #> $content$records[[1]]$evidence_direction #> [1] "Supports" #> #> $content$records[[1]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[1]]$drug_interaction_type #> NULL #> #> $content$records[[1]]$status #> [1] "accepted" #> #> $content$records[[1]]$open_change_count #> [1] 0 #> #> $content$records[[1]]$type #> [1] "evidence" #> #> $content$records[[1]]$source #> $content$records[[1]]$source$id #> [1] 51 #> #> $content$records[[1]]$source$name #> [1] "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia." #> #> $content$records[[1]]$source$citation #> [1] "Levine et al., 2005, Blood" #> #> $content$records[[1]]$source$citation_id #> [1] "16081687" #> #> $content$records[[1]]$source$source_type #> [1] "PubMed" #> #> $content$records[[1]]$source$asco_abstract_id #> NULL #> #> $content$records[[1]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/16081687" #> #> $content$records[[1]]$source$open_access #> [1] TRUE #> #> $content$records[[1]]$source$pmc_id #> [1] "PMC1895066" #> #> $content$records[[1]]$source$publication_date #> $content$records[[1]]$source$publication_date$year #> [1] 2005 #> #> $content$records[[1]]$source$publication_date$month #> [1] 11 #> #> $content$records[[1]]$source$publication_date$day #> [1] 15 #> #> #> $content$records[[1]]$source$journal #> [1] "Blood" #> #> $content$records[[1]]$source$full_journal_title #> [1] "Blood" #> #> $content$records[[1]]$source$status #> [1] "fully curated" #> #> $content$records[[1]]$source$is_review #> [1] FALSE #> #> $content$records[[1]]$source$clinical_trials #> list() #> #> #> $content$records[[1]]$variant_id #> [1] 64 #> #> $content$records[[1]]$phenotypes #> list() #> #> #> $content$records[[2]] #> $content$records[[2]]$id #> [1] 2 #> #> $content$records[[2]]$name #> [1] "EID2" #> #> $content$records[[2]]$description #> [1] "GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant." #> #> $content$records[[2]]$disease #> $content$records[[2]]$disease$id #> [1] 2 #> #> $content$records[[2]]$disease$name #> [1] "Gastrointestinal Stromal Tumor" #> #> $content$records[[2]]$disease$display_name #> [1] "Gastrointestinal Stromal Tumor" #> #> $content$records[[2]]$disease$doid #> [1] "9253" #> #> $content$records[[2]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:9253" #> #> #> $content$records[[2]]$drugs #> list() #> #> $content$records[[2]]$rating #> [1] 3 #> #> $content$records[[2]]$evidence_level #> [1] "B" #> #> $content$records[[2]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[2]]$clinical_significance #> [1] "Negative" #> #> $content$records[[2]]$evidence_direction #> [1] "Supports" #> #> $content$records[[2]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[2]]$drug_interaction_type #> NULL #> #> $content$records[[2]]$status #> [1] "accepted" #> #> $content$records[[2]]$open_change_count #> [1] 0 #> #> $content$records[[2]]$type #> [1] "evidence" #> #> $content$records[[2]]$source #> $content$records[[2]]$source$id #> [1] 52 #> #> $content$records[[2]]$source$name #> [1] "A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential." #> #> $content$records[[2]]$source$citation #> [1] "Lasota et al., 2004, Lab. Invest." #> #> $content$records[[2]]$source$citation_id #> [1] "15146165" #> #> $content$records[[2]]$source$source_type #> [1] "PubMed" #> #> $content$records[[2]]$source$asco_abstract_id #> NULL #> #> $content$records[[2]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/15146165" #> #> $content$records[[2]]$source$open_access #> NULL #> #> $content$records[[2]]$source$pmc_id #> NULL #> #> $content$records[[2]]$source$publication_date #> $content$records[[2]]$source$publication_date$year #> [1] 2004 #> #> $content$records[[2]]$source$publication_date$month #> [1] 7 #> #> #> $content$records[[2]]$source$journal #> [1] "Lab. Invest." #> #> $content$records[[2]]$source$full_journal_title #> [1] "Laboratory investigation; a journal of technical methods and pathology" #> #> $content$records[[2]]$source$status #> [1] "fully curated" #> #> $content$records[[2]]$source$is_review #> [1] FALSE #> #> $content$records[[2]]$source$clinical_trials #> list() #> #> #> $content$records[[2]]$variant_id #> [1] 99 #> #> $content$records[[2]]$phenotypes #> list() #> #> #> $content$records[[3]] #> $content$records[[3]]$id #> [1] 3 #> #> $content$records[[3]]$name #> [1] "EID3" #> #> $content$records[[3]]$description #> [1] "DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk)." #> #> $content$records[[3]]$disease #> $content$records[[3]]$disease$id #> [1] 3 #> #> $content$records[[3]]$disease$name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[3]]$disease$display_name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[3]]$disease$doid #> [1] "9119" #> #> $content$records[[3]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:9119" #> #> #> $content$records[[3]]$drugs #> list() #> #> $content$records[[3]]$rating #> [1] 2 #> #> $content$records[[3]]$evidence_level #> [1] "B" #> #> $content$records[[3]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[3]]$clinical_significance #> [1] "Positive" #> #> $content$records[[3]]$evidence_direction #> [1] "Supports" #> #> $content$records[[3]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[3]]$drug_interaction_type #> NULL #> #> $content$records[[3]]$status #> [1] "accepted" #> #> $content$records[[3]]$open_change_count #> [1] 0 #> #> $content$records[[3]]$type #> [1] "evidence" #> #> $content$records[[3]]$source #> $content$records[[3]]$source$id #> [1] 53 #> #> $content$records[[3]]$source$name #> [1] "Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience." #> #> $content$records[[3]]$source$citation #> [1] "LaRochelle et al., 2011, Oncotarget" #> #> $content$records[[3]]$source$citation_id #> [1] "22081665" #> #> $content$records[[3]]$source$source_type #> [1] "PubMed" #> #> $content$records[[3]]$source$asco_abstract_id #> NULL #> #> $content$records[[3]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/22081665" #> #> $content$records[[3]]$source$open_access #> [1] TRUE #> #> $content$records[[3]]$source$pmc_id #> [1] "PMC3260002" #> #> $content$records[[3]]$source$publication_date #> $content$records[[3]]$source$publication_date$year #> [1] 2011 #> #> $content$records[[3]]$source$publication_date$month #> [1] 11 #> #> #> $content$records[[3]]$source$journal #> [1] "Oncotarget" #> #> $content$records[[3]]$source$full_journal_title #> [1] "Oncotarget" #> #> $content$records[[3]]$source$status #> [1] "partially curated" #> #> $content$records[[3]]$source$is_review #> [1] FALSE #> #> $content$records[[3]]$source$clinical_trials #> list() #> #> #> $content$records[[3]]$variant_id #> [1] 32 #> #> $content$records[[3]]$phenotypes #> list() #> #> #> $content$records[[4]] #> $content$records[[4]]$id #> [1] 4 #> #> $content$records[[4]]$name #> [1] "EID4" #> #> $content$records[[4]]$description #> [1] "Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A." #> #> $content$records[[4]]$disease #> $content$records[[4]]$disease$id #> [1] 3 #> #> $content$records[[4]]$disease$name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[4]]$disease$display_name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[4]]$disease$doid #> [1] "9119" #> #> $content$records[[4]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:9119" #> #> #> $content$records[[4]]$drugs #> list() #> #> $content$records[[4]]$rating #> [1] 3 #> #> $content$records[[4]]$evidence_level #> [1] "B" #> #> $content$records[[4]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[4]]$clinical_significance #> [1] "Positive" #> #> $content$records[[4]]$evidence_direction #> [1] "Supports" #> #> $content$records[[4]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[4]]$drug_interaction_type #> NULL #> #> $content$records[[4]]$status #> [1] "accepted" #> #> $content$records[[4]]$open_change_count #> [1] 0 #> #> $content$records[[4]]$type #> [1] "evidence" #> #> $content$records[[4]]$source #> $content$records[[4]]$source$id #> [1] 54 #> #> $content$records[[4]]$source$name #> [1] "Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia." #> #> $content$records[[4]]$source$citation #> [1] "Ribeiro et al., 2012, Blood" #> #> $content$records[[4]]$source$citation_id #> [1] "22490330" #> #> $content$records[[4]]$source$source_type #> [1] "PubMed" #> #> $content$records[[4]]$source$asco_abstract_id #> NULL #> #> $content$records[[4]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/22490330" #> #> $content$records[[4]]$source$open_access #> NULL #> #> $content$records[[4]]$source$pmc_id #> NULL #> #> $content$records[[4]]$source$publication_date #> $content$records[[4]]$source$publication_date$year #> [1] 2012 #> #> $content$records[[4]]$source$publication_date$month #> [1] 6 #> #> $content$records[[4]]$source$publication_date$day #> [1] 14 #> #> #> $content$records[[4]]$source$journal #> [1] "Blood" #> #> $content$records[[4]]$source$full_journal_title #> [1] "Blood" #> #> $content$records[[4]]$source$status #> [1] "fully curated" #> #> $content$records[[4]]$source$is_review #> [1] FALSE #> #> $content$records[[4]]$source$clinical_trials #> list() #> #> #> $content$records[[4]]$variant_id #> [1] 32 #> #> $content$records[[4]]$phenotypes #> list() #> #> #> $content$records[[5]] #> $content$records[[5]]$id #> [1] 5 #> #> $content$records[[5]]$name #> [1] "EID5" #> #> $content$records[[5]]$description #> [1] "JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML)." #> #> $content$records[[5]]$disease #> $content$records[[5]]$disease$id #> [1] 4 #> #> $content$records[[5]]$disease$name #> [1] "Chronic Myeloid Leukemia" #> #> $content$records[[5]]$disease$display_name #> [1] "Chronic Myeloid Leukemia" #> #> $content$records[[5]]$disease$doid #> [1] "8552" #> #> $content$records[[5]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:8552" #> #> #> $content$records[[5]]$drugs #> list() #> #> $content$records[[5]]$rating #> [1] 4 #> #> $content$records[[5]]$evidence_level #> [1] "B" #> #> $content$records[[5]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[5]]$clinical_significance #> [1] "Positive" #> #> $content$records[[5]]$evidence_direction #> [1] "Supports" #> #> $content$records[[5]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[5]]$drug_interaction_type #> NULL #> #> $content$records[[5]]$status #> [1] "accepted" #> #> $content$records[[5]]$open_change_count #> [1] 0 #> #> $content$records[[5]]$type #> [1] "evidence" #> #> $content$records[[5]]$source #> $content$records[[5]]$source$id #> [1] 51 #> #> $content$records[[5]]$source$name #> [1] "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia." #> #> $content$records[[5]]$source$citation #> [1] "Levine et al., 2005, Blood" #> #> $content$records[[5]]$source$citation_id #> [1] "16081687" #> #> $content$records[[5]]$source$source_type #> [1] "PubMed" #> #> $content$records[[5]]$source$asco_abstract_id #> NULL #> #> $content$records[[5]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/16081687" #> #> $content$records[[5]]$source$open_access #> [1] TRUE #> #> $content$records[[5]]$source$pmc_id #> [1] "PMC1895066" #> #> $content$records[[5]]$source$publication_date #> $content$records[[5]]$source$publication_date$year #> [1] 2005 #> #> $content$records[[5]]$source$publication_date$month #> [1] 11 #> #> $content$records[[5]]$source$publication_date$day #> [1] 15 #> #> #> $content$records[[5]]$source$journal #> [1] "Blood" #> #> $content$records[[5]]$source$full_journal_title #> [1] "Blood" #> #> $content$records[[5]]$source$status #> [1] "fully curated" #> #> $content$records[[5]]$source$is_review #> [1] FALSE #> #> $content$records[[5]]$source$clinical_trials #> list() #> #> #> $content$records[[5]]$variant_id #> [1] 64 #> #> $content$records[[5]]$phenotypes #> list() #> #> #> $content$records[[6]] #> $content$records[[6]]$id #> [1] 7 #> #> $content$records[[6]]$name #> [1] "EID7" #> #> $content$records[[6]]$description #> [1] "The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer." #> #> $content$records[[6]]$disease #> $content$records[[6]]$disease$id #> [1] 5 #> #> $content$records[[6]]$disease$name #> [1] "Bone Marrow Cancer" #> #> $content$records[[6]]$disease$display_name #> [1] "Bone Marrow Cancer" #> #> $content$records[[6]]$disease$doid #> [1] "4960" #> #> $content$records[[6]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:4960" #> #> #> $content$records[[6]]$drugs #> list() #> #> $content$records[[6]]$rating #> [1] 4 #> #> $content$records[[6]]$evidence_level #> [1] "B" #> #> $content$records[[6]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[6]]$clinical_significance #> [1] "Positive" #> #> $content$records[[6]]$evidence_direction #> [1] "Supports" #> #> $content$records[[6]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[6]]$drug_interaction_type #> NULL #> #> $content$records[[6]]$status #> [1] "accepted" #> #> $content$records[[6]]$open_change_count #> [1] 0 #> #> $content$records[[6]]$type #> [1] "evidence" #> #> $content$records[[6]]$source #> $content$records[[6]]$source$id #> [1] 55 #> #> $content$records[[6]]$source$name #> [1] "A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms." #> #> $content$records[[6]]$source$citation #> [1] "Kilpivaara et al., 2009, Nat. Genet." #> #> $content$records[[6]]$source$citation_id #> [1] "19287384" #> #> $content$records[[6]]$source$source_type #> [1] "PubMed" #> #> $content$records[[6]]$source$asco_abstract_id #> NULL #> #> $content$records[[6]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/19287384" #> #> $content$records[[6]]$source$open_access #> [1] TRUE #> #> $content$records[[6]]$source$pmc_id #> [1] "PMC3676425" #> #> $content$records[[6]]$source$publication_date #> $content$records[[6]]$source$publication_date$year #> [1] 2009 #> #> $content$records[[6]]$source$publication_date$month #> [1] 4 #> #> #> $content$records[[6]]$source$journal #> [1] "Nat. Genet." #> #> $content$records[[6]]$source$full_journal_title #> [1] "Nature genetics" #> #> $content$records[[6]]$source$status #> [1] "fully curated" #> #> $content$records[[6]]$source$is_review #> [1] FALSE #> #> $content$records[[6]]$source$clinical_trials #> list() #> #> #> $content$records[[6]]$variant_id #> [1] 64 #> #> $content$records[[6]]$phenotypes #> list() #> #> #> $content$records[[7]] #> $content$records[[7]]$id #> [1] 8 #> #> $content$records[[7]]$name #> [1] "EID8" #> #> $content$records[[7]]$description #> [1] "Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation." #> #> $content$records[[7]]$disease #> $content$records[[7]]$disease$id #> [1] 6 #> #> $content$records[[7]]$disease$name #> [1] "Acute Leukemia" #> #> $content$records[[7]]$disease$display_name #> [1] "Acute Leukemia" #> #> $content$records[[7]]$disease$doid #> [1] "12603" #> #> $content$records[[7]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:12603" #> #> #> $content$records[[7]]$drugs #> list() #> #> $content$records[[7]]$rating #> [1] 3 #> #> $content$records[[7]]$evidence_level #> [1] "B" #> #> $content$records[[7]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[7]]$clinical_significance #> [1] "Positive" #> #> $content$records[[7]]$evidence_direction #> [1] "Supports" #> #> $content$records[[7]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[7]]$drug_interaction_type #> NULL #> #> $content$records[[7]]$status #> [1] "accepted" #> #> $content$records[[7]]$open_change_count #> [1] 0 #> #> $content$records[[7]]$type #> [1] "evidence" #> #> $content$records[[7]]$source #> $content$records[[7]]$source$id #> [1] 56 #> #> $content$records[[7]]$source$name #> [1] "RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures." #> #> $content$records[[7]]$source$citation #> [1] "Andrade et al., 2014, BMC Cancer" #> #> $content$records[[7]]$source$citation_id #> [1] "24571676" #> #> $content$records[[7]]$source$source_type #> [1] "PubMed" #> #> $content$records[[7]]$source$asco_abstract_id #> NULL #> #> $content$records[[7]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/24571676" #> #> $content$records[[7]]$source$open_access #> [1] TRUE #> #> $content$records[[7]]$source$pmc_id #> [1] "PMC3946262" #> #> $content$records[[7]]$source$publication_date #> $content$records[[7]]$source$publication_date$year #> [1] 2014 #> #> #> $content$records[[7]]$source$journal #> [1] "BMC Cancer" #> #> $content$records[[7]]$source$full_journal_title #> [1] "BMC cancer" #> #> $content$records[[7]]$source$status #> [1] "fully curated" #> #> $content$records[[7]]$source$is_review #> [1] FALSE #> #> $content$records[[7]]$source$clinical_trials #> list() #> #> #> $content$records[[7]]$variant_id #> [1] 76 #> #> $content$records[[7]]$phenotypes #> list() #> #> #> $content$records[[8]] #> $content$records[[8]]$id #> [1] 10 #> #> $content$records[[8]]$name #> [1] "EID10" #> #> $content$records[[8]]$description #> [1] "Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk." #> #> $content$records[[8]]$disease #> $content$records[[8]]$disease$id #> [1] 7 #> #> $content$records[[8]]$disease$name #> [1] "Melanoma" #> #> $content$records[[8]]$disease$display_name #> [1] "Melanoma" #> #> $content$records[[8]]$disease$doid #> [1] "1909" #> #> $content$records[[8]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:1909" #> #> #> $content$records[[8]]$drugs #> list() #> #> $content$records[[8]]$rating #> [1] 3 #> #> $content$records[[8]]$evidence_level #> [1] "B" #> #> $content$records[[8]]$evidence_type #> [1] "Diagnostic" #> #> $content$records[[8]]$clinical_significance #> [1] "Positive" #> #> $content$records[[8]]$evidence_direction #> [1] "Supports" #> #> $content$records[[8]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[8]]$drug_interaction_type #> NULL #> #> $content$records[[8]]$status #> [1] "accepted" #> #> $content$records[[8]]$open_change_count #> [1] 0 #> #> $content$records[[8]]$type #> [1] "evidence" #> #> $content$records[[8]]$source #> $content$records[[8]]$source$id #> [1] 57 #> #> $content$records[[8]]$source$name #> [1] "NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi." #> #> $content$records[[8]]$source$citation #> [1] "Tschandl et al., 2013, PLoS ONE" #> #> $content$records[[8]]$source$citation_id #> [1] "23861977" #> #> $content$records[[8]]$source$source_type #> [1] "PubMed" #> #> $content$records[[8]]$source$asco_abstract_id #> NULL #> #> $content$records[[8]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/23861977" #> #> $content$records[[8]]$source$open_access #> [1] TRUE #> #> $content$records[[8]]$source$pmc_id #> [1] "PMC3704624" #> #> $content$records[[8]]$source$publication_date #> $content$records[[8]]$source$publication_date$year #> [1] 2013 #> #> #> $content$records[[8]]$source$journal #> [1] "PLoS ONE" #> #> $content$records[[8]]$source$full_journal_title #> [1] "PloS one" #> #> $content$records[[8]]$source$status #> [1] "fully curated" #> #> $content$records[[8]]$source$is_review #> [1] FALSE #> #> $content$records[[8]]$source$clinical_trials #> list() #> #> #> $content$records[[8]]$variant_id #> [1] 94 #> #> $content$records[[8]]$phenotypes #> list() #> #> #> $content$records[[9]] #> $content$records[[9]]$id #> [1] 11 #> #> $content$records[[9]]$name #> [1] "EID11" #> #> $content$records[[9]]$description #> [1] "Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation." #> #> $content$records[[9]]$disease #> $content$records[[9]]$disease$id #> [1] 3 #> #> $content$records[[9]]$disease$name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[9]]$disease$display_name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[9]]$disease$doid #> [1] "9119" #> #> $content$records[[9]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:9119" #> #> #> $content$records[[9]]$drugs #> $content$records[[9]]$drugs[[1]] #> $content$records[[9]]$drugs[[1]]$id #> [1] 2 #> #> $content$records[[9]]$drugs[[1]]$name #> [1] "Daunorubicin" #> #> $content$records[[9]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[9]]$rating #> [1] 4 #> #> $content$records[[9]]$evidence_level #> [1] "B" #> #> $content$records[[9]]$evidence_type #> [1] "Predictive" #> #> $content$records[[9]]$clinical_significance #> [1] "Resistance" #> #> $content$records[[9]]$evidence_direction #> [1] "Does Not Support" #> #> $content$records[[9]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[9]]$drug_interaction_type #> NULL #> #> $content$records[[9]]$status #> [1] "accepted" #> #> $content$records[[9]]$open_change_count #> [1] 0 #> #> $content$records[[9]]$type #> [1] "evidence" #> #> $content$records[[9]]$source #> $content$records[[9]]$source$id #> [1] 53 #> #> $content$records[[9]]$source$name #> [1] "Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience." #> #> $content$records[[9]]$source$citation #> [1] "LaRochelle et al., 2011, Oncotarget" #> #> $content$records[[9]]$source$citation_id #> [1] "22081665" #> #> $content$records[[9]]$source$source_type #> [1] "PubMed" #> #> $content$records[[9]]$source$asco_abstract_id #> NULL #> #> $content$records[[9]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/22081665" #> #> $content$records[[9]]$source$open_access #> [1] TRUE #> #> $content$records[[9]]$source$pmc_id #> [1] "PMC3260002" #> #> $content$records[[9]]$source$publication_date #> $content$records[[9]]$source$publication_date$year #> [1] 2011 #> #> $content$records[[9]]$source$publication_date$month #> [1] 11 #> #> #> $content$records[[9]]$source$journal #> [1] "Oncotarget" #> #> $content$records[[9]]$source$full_journal_title #> [1] "Oncotarget" #> #> $content$records[[9]]$source$status #> [1] "partially curated" #> #> $content$records[[9]]$source$is_review #> [1] FALSE #> #> $content$records[[9]]$source$clinical_trials #> list() #> #> #> $content$records[[9]]$variant_id #> [1] 32 #> #> $content$records[[9]]$phenotypes #> list() #> #> #> $content$records[[10]] #> $content$records[[10]]$id #> [1] 12 #> #> $content$records[[10]]$name #> [1] "EID12" #> #> $content$records[[10]]$description #> [1] "A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells." #> #> $content$records[[10]]$disease #> $content$records[[10]]$disease$id #> [1] 7 #> #> $content$records[[10]]$disease$name #> [1] "Melanoma" #> #> $content$records[[10]]$disease$display_name #> [1] "Melanoma" #> #> $content$records[[10]]$disease$doid #> [1] "1909" #> #> $content$records[[10]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:1909" #> #> #> $content$records[[10]]$drugs #> $content$records[[10]]$drugs[[1]] #> $content$records[[10]]$drugs[[1]]$id #> [1] 122 #> #> $content$records[[10]]$drugs[[1]]$name #> [1] "Selumetinib" #> #> $content$records[[10]]$drugs[[1]]$pubchem_id #> [1] "" #> #> #> #> $content$records[[10]]$rating #> [1] 3 #> #> $content$records[[10]]$evidence_level #> [1] "D" #> #> $content$records[[10]]$evidence_type #> [1] "Predictive" #> #> $content$records[[10]]$clinical_significance #> [1] "Resistance" #> #> $content$records[[10]]$evidence_direction #> [1] "Supports" #> #> $content$records[[10]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[10]]$drug_interaction_type #> NULL #> #> $content$records[[10]]$status #> [1] "accepted" #> #> $content$records[[10]]$open_change_count #> [1] 0 #> #> $content$records[[10]]$type #> [1] "evidence" #> #> $content$records[[10]]$source #> $content$records[[10]]$source$id #> [1] 58 #> #> $content$records[[10]]$source$name #> [1] "MEK1 mutations confer resistance to MEK and B-RAF inhibition." #> #> $content$records[[10]]$source$citation #> [1] "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A." #> #> $content$records[[10]]$source$citation_id #> [1] "19915144" #> #> $content$records[[10]]$source$source_type #> [1] "PubMed" #> #> $content$records[[10]]$source$asco_abstract_id #> NULL #> #> $content$records[[10]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/19915144" #> #> $content$records[[10]]$source$open_access #> [1] TRUE #> #> $content$records[[10]]$source$pmc_id #> [1] "PMC2777185" #> #> $content$records[[10]]$source$publication_date #> $content$records[[10]]$source$publication_date$year #> [1] 2009 #> #> $content$records[[10]]$source$publication_date$month #> [1] 12 #> #> $content$records[[10]]$source$publication_date$day #> [1] 1 #> #> #> $content$records[[10]]$source$journal #> [1] "Proc. Natl. Acad. Sci. U.S.A." #> #> $content$records[[10]]$source$full_journal_title #> [1] "Proceedings of the National Academy of Sciences of the United States of America" #> #> $content$records[[10]]$source$status #> [1] "fully curated" #> #> $content$records[[10]]$source$is_review #> [1] FALSE #> #> $content$records[[10]]$source$clinical_trials #> list() #> #> #> $content$records[[10]]$variant_id #> [1] 82 #> #> $content$records[[10]]$phenotypes #> list() #> #> #> #> #> $url #> [1] "https://civicdb.org/api/evidence_items" #> #> $response #> Response [https://civicdb.org/api/evidence_items?page=1&count=10] #> Date: 2019-09-03 16:44 #> Status: 200 #> Content-Type: application/json; charset=utf-8 #> Size: 12.1 kB #> #> #> attr(,"class") #> [1] "civic_api"getAllEvidenceItems(page = 2, count = 10)#> $content #> $content$`_meta` #> $content$`_meta`$current_page #> [1] 2 #> #> $content$`_meta`$per_page #> [1] "10" #> #> $content$`_meta`$total_pages #> [1] 642 #> #> $content$`_meta`$total_count #> [1] 6411 #> #> $content$`_meta`$links #> $content$`_meta`$links$`next` #> [1] "https://civicdb.org/api/evidence_items?count=10&page=3" #> #> $content$`_meta`$links$previous #> [1] "https://civicdb.org/api/evidence_items?count=10&page=1" #> #> #> #> $content$records #> $content$records[[1]] #> $content$records[[1]]$id #> [1] 13 #> #> $content$records[[1]]$name #> [1] "EID13" #> #> $content$records[[1]]$description #> [1] "A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells." #> #> $content$records[[1]]$disease #> $content$records[[1]]$disease$id #> [1] 7 #> #> $content$records[[1]]$disease$name #> [1] "Melanoma" #> #> $content$records[[1]]$disease$display_name #> [1] "Melanoma" #> #> $content$records[[1]]$disease$doid #> [1] "1909" #> #> $content$records[[1]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:1909" #> #> #> $content$records[[1]]$drugs #> $content$records[[1]]$drugs[[1]] #> $content$records[[1]]$drugs[[1]]$id #> [1] 122 #> #> $content$records[[1]]$drugs[[1]]$name #> [1] "Selumetinib" #> #> $content$records[[1]]$drugs[[1]]$pubchem_id #> [1] "" #> #> #> #> $content$records[[1]]$rating #> [1] 3 #> #> $content$records[[1]]$evidence_level #> [1] "D" #> #> $content$records[[1]]$evidence_type #> [1] "Predictive" #> #> $content$records[[1]]$clinical_significance #> [1] "Resistance" #> #> $content$records[[1]]$evidence_direction #> [1] "Supports" #> #> $content$records[[1]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[1]]$drug_interaction_type #> NULL #> #> $content$records[[1]]$status #> [1] "accepted" #> #> $content$records[[1]]$open_change_count #> [1] 0 #> #> $content$records[[1]]$type #> [1] "evidence" #> #> $content$records[[1]]$source #> $content$records[[1]]$source$id #> [1] 58 #> #> $content$records[[1]]$source$name #> [1] "MEK1 mutations confer resistance to MEK and B-RAF inhibition." #> #> $content$records[[1]]$source$citation #> [1] "Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A." #> #> $content$records[[1]]$source$citation_id #> [1] "19915144" #> #> $content$records[[1]]$source$source_type #> [1] "PubMed" #> #> $content$records[[1]]$source$asco_abstract_id #> NULL #> #> $content$records[[1]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/19915144" #> #> $content$records[[1]]$source$open_access #> [1] TRUE #> #> $content$records[[1]]$source$pmc_id #> [1] "PMC2777185" #> #> $content$records[[1]]$source$publication_date #> $content$records[[1]]$source$publication_date$year #> [1] 2009 #> #> $content$records[[1]]$source$publication_date$month #> [1] 12 #> #> $content$records[[1]]$source$publication_date$day #> [1] 1 #> #> #> $content$records[[1]]$source$journal #> [1] "Proc. Natl. Acad. Sci. U.S.A." #> #> $content$records[[1]]$source$full_journal_title #> [1] "Proceedings of the National Academy of Sciences of the United States of America" #> #> $content$records[[1]]$source$status #> [1] "fully curated" #> #> $content$records[[1]]$source$is_review #> [1] FALSE #> #> $content$records[[1]]$source$clinical_trials #> list() #> #> #> $content$records[[1]]$variant_id #> [1] 83 #> #> $content$records[[1]]$phenotypes #> list() #> #> #> $content$records[[2]] #> $content$records[[2]]$id #> [1] 14 #> #> $content$records[[2]]$name #> [1] "EID14" #> #> $content$records[[2]]$description #> [1] "Vemurafenib resistance is associated with gain of Q61 mutation in NRAS." #> #> $content$records[[2]]$disease #> $content$records[[2]]$disease$id #> [1] 7 #> #> $content$records[[2]]$disease$name #> [1] "Melanoma" #> #> $content$records[[2]]$disease$display_name #> [1] "Melanoma" #> #> $content$records[[2]]$disease$doid #> [1] "1909" #> #> $content$records[[2]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:1909" #> #> #> $content$records[[2]]$drugs #> $content$records[[2]]$drugs[[1]] #> $content$records[[2]]$drugs[[1]]$id #> [1] 4 #> #> $content$records[[2]]$drugs[[1]]$name #> [1] "Vemurafenib" #> #> $content$records[[2]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[2]]$rating #> [1] 4 #> #> $content$records[[2]]$evidence_level #> [1] "B" #> #> $content$records[[2]]$evidence_type #> [1] "Predictive" #> #> $content$records[[2]]$clinical_significance #> [1] "Resistance" #> #> $content$records[[2]]$evidence_direction #> [1] "Supports" #> #> $content$records[[2]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[2]]$drug_interaction_type #> NULL #> #> $content$records[[2]]$status #> [1] "accepted" #> #> $content$records[[2]]$open_change_count #> [1] 0 #> #> $content$records[[2]]$type #> [1] "evidence" #> #> $content$records[[2]]$source #> $content$records[[2]]$source$id #> [1] 60 #> #> $content$records[[2]]$source$name #> [1] "Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma." #> #> $content$records[[2]]$source$citation #> [1] "Trunzer et al., 2013, J. Clin. Oncol." #> #> $content$records[[2]]$source$citation_id #> [1] "23569304" #> #> $content$records[[2]]$source$source_type #> [1] "PubMed" #> #> $content$records[[2]]$source$asco_abstract_id #> NULL #> #> $content$records[[2]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/23569304" #> #> $content$records[[2]]$source$open_access #> NULL #> #> $content$records[[2]]$source$pmc_id #> NULL #> #> $content$records[[2]]$source$publication_date #> $content$records[[2]]$source$publication_date$year #> [1] 2013 #> #> $content$records[[2]]$source$publication_date$month #> [1] 5 #> #> $content$records[[2]]$source$publication_date$day #> [1] 10 #> #> #> $content$records[[2]]$source$journal #> [1] "J. Clin. Oncol." #> #> $content$records[[2]]$source$full_journal_title #> [1] "Journal of clinical oncology : official journal of the American Society of Clinical Oncology" #> #> $content$records[[2]]$source$status #> [1] "fully curated" #> #> $content$records[[2]]$source$is_review #> [1] FALSE #> #> $content$records[[2]]$source$clinical_trials #> list() #> #> #> $content$records[[2]]$variant_id #> [1] 94 #> #> $content$records[[2]]$phenotypes #> list() #> #> #> $content$records[[3]] #> $content$records[[3]]$id #> [1] 15 #> #> $content$records[[3]]$name #> [1] "EID15" #> #> $content$records[[3]]$description #> [1] "GIST cancer with D842V mutation is resistant to imatinib." #> #> $content$records[[3]]$disease #> $content$records[[3]]$disease$id #> [1] 2 #> #> $content$records[[3]]$disease$name #> [1] "Gastrointestinal Stromal Tumor" #> #> $content$records[[3]]$disease$display_name #> [1] "Gastrointestinal Stromal Tumor" #> #> $content$records[[3]]$disease$doid #> [1] "9253" #> #> $content$records[[3]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:9253" #> #> #> $content$records[[3]]$drugs #> $content$records[[3]]$drugs[[1]] #> $content$records[[3]]$drugs[[1]]$id #> [1] 5 #> #> $content$records[[3]]$drugs[[1]]$name #> [1] "Imatinib" #> #> $content$records[[3]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[3]]$rating #> [1] 4 #> #> $content$records[[3]]$evidence_level #> [1] "B" #> #> $content$records[[3]]$evidence_type #> [1] "Predictive" #> #> $content$records[[3]]$clinical_significance #> [1] "Resistance" #> #> $content$records[[3]]$evidence_direction #> [1] "Supports" #> #> $content$records[[3]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[3]]$drug_interaction_type #> NULL #> #> $content$records[[3]]$status #> [1] "accepted" #> #> $content$records[[3]]$open_change_count #> [1] 0 #> #> $content$records[[3]]$type #> [1] "evidence" #> #> $content$records[[3]]$source #> $content$records[[3]]$source$id #> [1] 61 #> #> $content$records[[3]]$source$name #> [1] "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib." #> #> $content$records[[3]]$source$citation #> [1] "Corless et al., 2005, J. Clin. Oncol." #> #> $content$records[[3]]$source$citation_id #> [1] "15928335" #> #> $content$records[[3]]$source$source_type #> [1] "PubMed" #> #> $content$records[[3]]$source$asco_abstract_id #> NULL #> #> $content$records[[3]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/15928335" #> #> $content$records[[3]]$source$open_access #> NULL #> #> $content$records[[3]]$source$pmc_id #> NULL #> #> $content$records[[3]]$source$publication_date #> $content$records[[3]]$source$publication_date$year #> [1] 2005 #> #> $content$records[[3]]$source$publication_date$month #> [1] 8 #> #> $content$records[[3]]$source$publication_date$day #> [1] 10 #> #> #> $content$records[[3]]$source$journal #> [1] "J. Clin. Oncol." #> #> $content$records[[3]]$source$full_journal_title #> [1] "Journal of clinical oncology : official journal of the American Society of Clinical Oncology" #> #> $content$records[[3]]$source$status #> [1] "fully curated" #> #> $content$records[[3]]$source$is_review #> [1] FALSE #> #> $content$records[[3]]$source$clinical_trials #> list() #> #> #> $content$records[[3]]$variant_id #> [1] 99 #> #> $content$records[[3]]$phenotypes #> list() #> #> #> $content$records[[4]] #> $content$records[[4]]$id #> [1] 16 #> #> $content$records[[4]]$name #> [1] "EID16" #> #> $content$records[[4]]$description #> [1] "While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib." #> #> $content$records[[4]]$disease #> $content$records[[4]]$disease$id #> [1] 2 #> #> $content$records[[4]]$disease$name #> [1] "Gastrointestinal Stromal Tumor" #> #> $content$records[[4]]$disease$display_name #> [1] "Gastrointestinal Stromal Tumor" #> #> $content$records[[4]]$disease$doid #> [1] "9253" #> #> $content$records[[4]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:9253" #> #> #> $content$records[[4]]$drugs #> $content$records[[4]]$drugs[[1]] #> $content$records[[4]]$drugs[[1]]$id #> [1] 5 #> #> $content$records[[4]]$drugs[[1]]$name #> [1] "Imatinib" #> #> $content$records[[4]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[4]]$rating #> [1] 4 #> #> $content$records[[4]]$evidence_level #> [1] "B" #> #> $content$records[[4]]$evidence_type #> [1] "Predictive" #> #> $content$records[[4]]$clinical_significance #> [1] "Resistance" #> #> $content$records[[4]]$evidence_direction #> [1] "Supports" #> #> $content$records[[4]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[4]]$drug_interaction_type #> NULL #> #> $content$records[[4]]$status #> [1] "accepted" #> #> $content$records[[4]]$open_change_count #> [1] 0 #> #> $content$records[[4]]$type #> [1] "evidence" #> #> $content$records[[4]]$source #> $content$records[[4]]$source$id #> [1] 62 #> #> $content$records[[4]]$source$name #> [1] "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors." #> #> $content$records[[4]]$source$citation #> [1] "Heinrich et al., 2006, J. Clin. Oncol." #> #> $content$records[[4]]$source$citation_id #> [1] "16954519" #> #> $content$records[[4]]$source$source_type #> [1] "PubMed" #> #> $content$records[[4]]$source$asco_abstract_id #> NULL #> #> $content$records[[4]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/16954519" #> #> $content$records[[4]]$source$open_access #> NULL #> #> $content$records[[4]]$source$pmc_id #> NULL #> #> $content$records[[4]]$source$publication_date #> $content$records[[4]]$source$publication_date$year #> [1] 2006 #> #> $content$records[[4]]$source$publication_date$month #> [1] 10 #> #> $content$records[[4]]$source$publication_date$day #> [1] 10 #> #> #> $content$records[[4]]$source$journal #> [1] "J. Clin. Oncol." #> #> $content$records[[4]]$source$full_journal_title #> [1] "Journal of clinical oncology : official journal of the American Society of Clinical Oncology" #> #> $content$records[[4]]$source$status #> [1] "partially curated" #> #> $content$records[[4]]$source$is_review #> [1] FALSE #> #> $content$records[[4]]$source$clinical_trials #> list() #> #> #> $content$records[[4]]$variant_id #> [1] 99 #> #> $content$records[[4]]$phenotypes #> list() #> #> #> $content$records[[5]] #> $content$records[[5]]$id #> [1] 17 #> #> $content$records[[5]]$name #> [1] "EID17" #> #> $content$records[[5]]$description #> [1] "In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission." #> #> $content$records[[5]]$disease #> $content$records[[5]]$disease$id #> [1] 8 #> #> $content$records[[5]]$disease$name #> [1] "Lung Non-small Cell Carcinoma" #> #> $content$records[[5]]$disease$display_name #> [1] "Lung Non-small Cell Carcinoma" #> #> $content$records[[5]]$disease$doid #> [1] "3908" #> #> $content$records[[5]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:3908" #> #> #> $content$records[[5]]$drugs #> $content$records[[5]]$drugs[[1]] #> $content$records[[5]]$drugs[[1]]$id #> [1] 6 #> #> $content$records[[5]]$drugs[[1]]$name #> [1] "Sorafenib" #> #> $content$records[[5]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[5]]$rating #> [1] 2 #> #> $content$records[[5]]$evidence_level #> [1] "C" #> #> $content$records[[5]]$evidence_type #> [1] "Predictive" #> #> $content$records[[5]]$clinical_significance #> [1] "Sensitivity/Response" #> #> $content$records[[5]]$evidence_direction #> [1] "Supports" #> #> $content$records[[5]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[5]]$drug_interaction_type #> NULL #> #> $content$records[[5]]$status #> [1] "accepted" #> #> $content$records[[5]]$open_change_count #> [1] 0 #> #> $content$records[[5]]$type #> [1] "evidence" #> #> $content$records[[5]]$source #> $content$records[[5]]$source$id #> [1] 6 #> #> $content$records[[5]]$source$name #> [1] "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma." #> #> $content$records[[5]]$source$citation #> [1] "Imielinski et al., 2014, J. Clin. Invest." #> #> $content$records[[5]]$source$citation_id #> [1] "24569458" #> #> $content$records[[5]]$source$source_type #> [1] "PubMed" #> #> $content$records[[5]]$source$asco_abstract_id #> NULL #> #> $content$records[[5]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/24569458" #> #> $content$records[[5]]$source$open_access #> [1] TRUE #> #> $content$records[[5]]$source$pmc_id #> [1] "PMC3973082" #> #> $content$records[[5]]$source$publication_date #> $content$records[[5]]$source$publication_date$year #> [1] 2014 #> #> $content$records[[5]]$source$publication_date$month #> [1] 4 #> #> #> $content$records[[5]]$source$journal #> [1] "J. Clin. Invest." #> #> $content$records[[5]]$source$full_journal_title #> [1] "The Journal of clinical investigation" #> #> $content$records[[5]]$source$status #> [1] "fully curated" #> #> $content$records[[5]]$source$is_review #> [1] FALSE #> #> $content$records[[5]]$source$clinical_trials #> list() #> #> #> $content$records[[5]]$variant_id #> [1] 10 #> #> $content$records[[5]]$phenotypes #> list() #> #> #> $content$records[[6]] #> $content$records[[6]]$id #> [1] 18 #> #> $content$records[[6]]$name #> [1] "EID18" #> #> $content$records[[6]]$description #> [1] "Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation." #> #> $content$records[[6]]$disease #> $content$records[[6]]$disease$id #> [1] 3 #> #> $content$records[[6]]$disease$name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[6]]$disease$display_name #> [1] "Acute Myeloid Leukemia" #> #> $content$records[[6]]$disease$doid #> [1] "9119" #> #> $content$records[[6]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:9119" #> #> #> $content$records[[6]]$drugs #> $content$records[[6]]$drugs[[1]] #> $content$records[[6]]$drugs[[1]]$id #> [1] 7 #> #> $content$records[[6]]$drugs[[1]]$name #> [1] "Idarubicin" #> #> $content$records[[6]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[6]]$rating #> [1] 4 #> #> $content$records[[6]]$evidence_level #> [1] "B" #> #> $content$records[[6]]$evidence_type #> [1] "Predictive" #> #> $content$records[[6]]$clinical_significance #> [1] "Sensitivity/Response" #> #> $content$records[[6]]$evidence_direction #> [1] "Supports" #> #> $content$records[[6]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[6]]$drug_interaction_type #> NULL #> #> $content$records[[6]]$status #> [1] "accepted" #> #> $content$records[[6]]$open_change_count #> [1] 0 #> #> $content$records[[6]]$type #> [1] "evidence" #> #> $content$records[[6]]$source #> $content$records[[6]]$source$id #> [1] 53 #> #> $content$records[[6]]$source$name #> [1] "Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience." #> #> $content$records[[6]]$source$citation #> [1] "LaRochelle et al., 2011, Oncotarget" #> #> $content$records[[6]]$source$citation_id #> [1] "22081665" #> #> $content$records[[6]]$source$source_type #> [1] "PubMed" #> #> $content$records[[6]]$source$asco_abstract_id #> NULL #> #> $content$records[[6]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/22081665" #> #> $content$records[[6]]$source$open_access #> [1] TRUE #> #> $content$records[[6]]$source$pmc_id #> [1] "PMC3260002" #> #> $content$records[[6]]$source$publication_date #> $content$records[[6]]$source$publication_date$year #> [1] 2011 #> #> $content$records[[6]]$source$publication_date$month #> [1] 11 #> #> #> $content$records[[6]]$source$journal #> [1] "Oncotarget" #> #> $content$records[[6]]$source$full_journal_title #> [1] "Oncotarget" #> #> $content$records[[6]]$source$status #> [1] "partially curated" #> #> $content$records[[6]]$source$is_review #> [1] FALSE #> #> $content$records[[6]]$source$clinical_trials #> list() #> #> #> $content$records[[6]]$variant_id #> [1] 32 #> #> $content$records[[6]]$phenotypes #> list() #> #> #> $content$records[[7]] #> $content$records[[7]]$id #> [1] 19 #> #> $content$records[[7]]$name #> [1] "EID19" #> #> $content$records[[7]]$description #> [1] "In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F." #> #> $content$records[[7]]$disease #> $content$records[[7]]$disease$id #> [1] 9 #> #> $content$records[[7]]$disease$name #> [1] "Polycythemia Vera" #> #> $content$records[[7]]$disease$display_name #> [1] "Polycythemia Vera" #> #> $content$records[[7]]$disease$doid #> [1] "8997" #> #> $content$records[[7]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:8997" #> #> #> $content$records[[7]]$drugs #> $content$records[[7]]$drugs[[1]] #> $content$records[[7]]$drugs[[1]]$id #> [1] 8 #> #> $content$records[[7]]$drugs[[1]]$name #> [1] "Pegylated IFN-alpha-2a" #> #> $content$records[[7]]$drugs[[1]]$pubchem_id #> [1] "" #> #> #> #> $content$records[[7]]$rating #> [1] 4 #> #> $content$records[[7]]$evidence_level #> [1] "B" #> #> $content$records[[7]]$evidence_type #> [1] "Predictive" #> #> $content$records[[7]]$clinical_significance #> [1] "Sensitivity/Response" #> #> $content$records[[7]]$evidence_direction #> [1] "Supports" #> #> $content$records[[7]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[7]]$drug_interaction_type #> NULL #> #> $content$records[[7]]$status #> [1] "accepted" #> #> $content$records[[7]]$open_change_count #> [1] 1 #> #> $content$records[[7]]$type #> [1] "evidence" #> #> $content$records[[7]]$source #> $content$records[[7]]$source$id #> [1] 64 #> #> $content$records[[7]]$source$name #> [1] "High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a." #> #> $content$records[[7]]$source$citation #> [1] "Kiladjian et al., 2006, Blood" #> #> $content$records[[7]]$source$citation_id #> [1] "16709929" #> #> $content$records[[7]]$source$source_type #> [1] "PubMed" #> #> $content$records[[7]]$source$asco_abstract_id #> NULL #> #> $content$records[[7]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/16709929" #> #> $content$records[[7]]$source$open_access #> NULL #> #> $content$records[[7]]$source$pmc_id #> NULL #> #> $content$records[[7]]$source$publication_date #> $content$records[[7]]$source$publication_date$year #> [1] 2006 #> #> $content$records[[7]]$source$publication_date$month #> [1] 9 #> #> $content$records[[7]]$source$publication_date$day #> [1] 15 #> #> #> $content$records[[7]]$source$journal #> [1] "Blood" #> #> $content$records[[7]]$source$full_journal_title #> [1] "Blood" #> #> $content$records[[7]]$source$status #> [1] "fully curated" #> #> $content$records[[7]]$source$is_review #> [1] FALSE #> #> $content$records[[7]]$source$clinical_trials #> list() #> #> #> $content$records[[7]]$variant_id #> [1] 64 #> #> $content$records[[7]]$phenotypes #> list() #> #> #> $content$records[[8]] #> $content$records[[8]]$id #> [1] 20 #> #> $content$records[[8]]$name #> [1] "EID20" #> #> $content$records[[8]]$description #> [1] "TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells." #> #> $content$records[[8]]$disease #> $content$records[[8]]$disease$id #> [1] 9 #> #> $content$records[[8]]$disease$name #> [1] "Polycythemia Vera" #> #> $content$records[[8]]$disease$display_name #> [1] "Polycythemia Vera" #> #> $content$records[[8]]$disease$doid #> [1] "8997" #> #> $content$records[[8]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:8997" #> #> #> $content$records[[8]]$drugs #> $content$records[[8]]$drugs[[1]] #> $content$records[[8]]$drugs[[1]]$id #> [1] 9 #> #> $content$records[[8]]$drugs[[1]]$name #> [1] "TG101348" #> #> $content$records[[8]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[8]]$rating #> [1] 3 #> #> $content$records[[8]]$evidence_level #> [1] "D" #> #> $content$records[[8]]$evidence_type #> [1] "Predictive" #> #> $content$records[[8]]$clinical_significance #> [1] "Sensitivity/Response" #> #> $content$records[[8]]$evidence_direction #> [1] "Supports" #> #> $content$records[[8]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[8]]$drug_interaction_type #> NULL #> #> $content$records[[8]]$status #> [1] "accepted" #> #> $content$records[[8]]$open_change_count #> [1] 0 #> #> $content$records[[8]]$type #> [1] "evidence" #> #> $content$records[[8]]$source #> $content$records[[8]]$source$id #> [1] 65 #> #> $content$records[[8]]$source$name #> [1] "Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera." #> #> $content$records[[8]]$source$citation #> [1] "Wernig et al., 2008, Cancer Cell" #> #> $content$records[[8]]$source$citation_id #> [1] "18394554" #> #> $content$records[[8]]$source$source_type #> [1] "PubMed" #> #> $content$records[[8]]$source$asco_abstract_id #> NULL #> #> $content$records[[8]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/18394554" #> #> $content$records[[8]]$source$open_access #> NULL #> #> $content$records[[8]]$source$pmc_id #> NULL #> #> $content$records[[8]]$source$publication_date #> $content$records[[8]]$source$publication_date$year #> [1] 2008 #> #> $content$records[[8]]$source$publication_date$month #> [1] 4 #> #> #> $content$records[[8]]$source$journal #> [1] "Cancer Cell" #> #> $content$records[[8]]$source$full_journal_title #> [1] "Cancer cell" #> #> $content$records[[8]]$source$status #> [1] "fully curated" #> #> $content$records[[8]]$source$is_review #> [1] FALSE #> #> $content$records[[8]]$source$clinical_trials #> list() #> #> #> $content$records[[8]]$variant_id #> [1] 64 #> #> $content$records[[8]]$phenotypes #> list() #> #> #> $content$records[[9]] #> $content$records[[9]]$id #> [1] 21 #> #> $content$records[[9]]$name #> [1] "EID21" #> #> $content$records[[9]]$description #> [1] "Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation." #> #> $content$records[[9]]$disease #> $content$records[[9]]$disease$id #> [1] 7 #> #> $content$records[[9]]$disease$name #> [1] "Melanoma" #> #> $content$records[[9]]$disease$display_name #> [1] "Melanoma" #> #> $content$records[[9]]$disease$doid #> [1] "1909" #> #> $content$records[[9]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:1909" #> #> #> $content$records[[9]]$drugs #> $content$records[[9]]$drugs[[1]] #> $content$records[[9]]$drugs[[1]]$id #> [1] 10 #> #> $content$records[[9]]$drugs[[1]]$name #> [1] "17-AAG" #> #> $content$records[[9]]$drugs[[1]]$pubchem_id #> NULL #> #> #> #> $content$records[[9]]$rating #> [1] 2 #> #> $content$records[[9]]$evidence_level #> [1] "C" #> #> $content$records[[9]]$evidence_type #> [1] "Predictive" #> #> $content$records[[9]]$clinical_significance #> [1] "Sensitivity/Response" #> #> $content$records[[9]]$evidence_direction #> [1] "Supports" #> #> $content$records[[9]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[9]]$drug_interaction_type #> NULL #> #> $content$records[[9]]$status #> [1] "accepted" #> #> $content$records[[9]]$open_change_count #> [1] 0 #> #> $content$records[[9]]$type #> [1] "evidence" #> #> $content$records[[9]]$source #> $content$records[[9]]$source$id #> [1] 66 #> #> $content$records[[9]]$source$name #> [1] "BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors." #> #> $content$records[[9]]$source$citation #> [1] "Banerji et al., 2008, Mol. Cancer Ther." #> #> $content$records[[9]]$source$citation_id #> [1] "18375819" #> #> $content$records[[9]]$source$source_type #> [1] "PubMed" #> #> $content$records[[9]]$source$asco_abstract_id #> NULL #> #> $content$records[[9]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/18375819" #> #> $content$records[[9]]$source$open_access #> NULL #> #> $content$records[[9]]$source$pmc_id #> NULL #> #> $content$records[[9]]$source$publication_date #> $content$records[[9]]$source$publication_date$year #> [1] 2008 #> #> $content$records[[9]]$source$publication_date$month #> [1] 4 #> #> #> $content$records[[9]]$source$journal #> [1] "Mol. Cancer Ther." #> #> $content$records[[9]]$source$full_journal_title #> [1] "Molecular cancer therapeutics" #> #> $content$records[[9]]$source$status #> [1] "fully curated" #> #> $content$records[[9]]$source$is_review #> [1] FALSE #> #> $content$records[[9]]$source$clinical_trials #> list() #> #> #> $content$records[[9]]$variant_id #> [1] 93 #> #> $content$records[[9]]$phenotypes #> list() #> #> #> $content$records[[10]] #> $content$records[[10]]$id #> [1] 22 #> #> $content$records[[10]]$name #> [1] "EID22" #> #> $content$records[[10]]$description #> [1] "In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months." #> #> $content$records[[10]]$disease #> $content$records[[10]]$disease$id #> [1] 7 #> #> $content$records[[10]]$disease$name #> [1] "Melanoma" #> #> $content$records[[10]]$disease$display_name #> [1] "Melanoma" #> #> $content$records[[10]]$disease$doid #> [1] "1909" #> #> $content$records[[10]]$disease$url #> [1] "http://www.disease-ontology.org/?id=DOID:1909" #> #> #> $content$records[[10]]$drugs #> $content$records[[10]]$drugs[[1]] #> $content$records[[10]]$drugs[[1]]$id #> [1] 11 #> #> $content$records[[10]]$drugs[[1]]$name #> [1] "Temozolomide" #> #> $content$records[[10]]$drugs[[1]]$pubchem_id #> [1] "" #> #> #> #> $content$records[[10]]$rating #> [1] 2 #> #> $content$records[[10]]$evidence_level #> [1] "C" #> #> $content$records[[10]]$evidence_type #> [1] "Predictive" #> #> $content$records[[10]]$clinical_significance #> [1] "Sensitivity/Response" #> #> $content$records[[10]]$evidence_direction #> [1] "Supports" #> #> $content$records[[10]]$variant_origin #> [1] "Somatic Mutation" #> #> $content$records[[10]]$drug_interaction_type #> NULL #> #> $content$records[[10]]$status #> [1] "accepted" #> #> $content$records[[10]]$open_change_count #> [1] 0 #> #> $content$records[[10]]$type #> [1] "evidence" #> #> $content$records[[10]]$source #> $content$records[[10]]$source$id #> [1] 67 #> #> $content$records[[10]]$source$name #> [1] "NRAS-mutant melanoma: response to chemotherapy." #> #> $content$records[[10]]$source$citation #> [1] "Soon et al., 2011, Arch Dermatol" #> #> $content$records[[10]]$source$citation_id #> [1] "21576590" #> #> $content$records[[10]]$source$source_type #> [1] "PubMed" #> #> $content$records[[10]]$source$asco_abstract_id #> NULL #> #> $content$records[[10]]$source$source_url #> [1] "http://www.ncbi.nlm.nih.gov/pubmed/21576590" #> #> $content$records[[10]]$source$open_access #> NULL #> #> $content$records[[10]]$source$pmc_id #> NULL #> #> $content$records[[10]]$source$publication_date #> $content$records[[10]]$source$publication_date$year #> [1] 2011 #> #> $content$records[[10]]$source$publication_date$month #> [1] 5 #> #> #> $content$records[[10]]$source$journal #> [1] "Arch Dermatol" #> #> $content$records[[10]]$source$full_journal_title #> [1] "Archives of dermatology" #> #> $content$records[[10]]$source$status #> [1] "fully curated" #> #> $content$records[[10]]$source$is_review #> [1] FALSE #> #> $content$records[[10]]$source$clinical_trials #> list() #> #> #> $content$records[[10]]$variant_id #> [1] 95 #> #> $content$records[[10]]$phenotypes #> list() #> #> #> #> #> $url #> [1] "https://civicdb.org/api/evidence_items" #> #> $response #> Response [https://civicdb.org/api/evidence_items?page=2&count=10] #> Date: 2019-09-03 16:44 #> Status: 200 #> Content-Type: application/json; charset=utf-8 #> Size: 12.6 kB #> #> #> attr(,"class") #> [1] "civic_api"